21 / 60
21
Estudio hormonal en pacientes con cáncer de próstata
Alejandro Domínguez Amillo
clinical research progress on developing a PCA3 score. Chin J
Cancer Res. 2014; 26: 493-500.
6.
Lianidou ES, Strati A, Markou A. Circulating tumor cells as
promising novel biomarkers in solid cancers. Crit Rev Clin Lab
Sci. 2014; 51: 160-71.
7.
Bruzzese D, Mazzarella C, Ferro M et al. Prostate health index
vs percent free prostate-specific antigen for prostate cancer
detection in men with “gray” prostate-specific antigen levels
at first biopsy: systematic review and meta-analysis. Transl
Res. 2014; 164: 444-51.
8.
Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening
for prostate cancer. Cochrane Database Syst Rev. 2013;
doi:10.1002/14651858.CD004720.pub3.
9.
Léon P, Seisen T, Cussenot O et al. Low circulating free and
bioavailable testosterone levels as predictors of high-grade
tumors in patients undergoing radical prostatectomy for
localized prostate cancer. Urol Oncol. 2015. doi: 10.1016/j.
urolonc.2014.11.010
10. Kayali M, Balci M, Aslan Y, Bilgin O, Guzel O, Tuncel A, Atan
A. The relationship between prostate cancer and presence of
metabolic syndrome and late-onset hypogonadism. Urology.
2014; 84: 1448-52.
11. San Francisco IF, Rojas PA, DeWolf WC, Morgentaler A. Low
free testosterone levels predict disease reclassification in men
with prostate cancer undergoing active surveillance. BJU Int.
2014; 114: 229-35.
12. Cabral PH, Iwamoto MW, Fanni VS, Barros Lda R, Cardoso
SN, Mello LF, Glina S. Study of testosterone as a predictor of
tumor aggressiveness in patients with prostate cancer. Int
Braz J Urol. 2013; 39: 173-81.
13. Alsharef MM, Kahie A, Conradie M, Goad EA, Fourie T.
Association between low serum free testosterone and
adverse prognostic factors in men diagnosed with prostate
cancer in KwaZulu-Natal. S Afr J Surg. 2012; 50: 40-2.
14. García-Cruz E, Piqueras M, Huguet J, Peri L, Izquierdo L,
Musquera M, Franco A, Alvarez-Vijande R, Ribal MJ, Alcaraz A.
Low testosterone levels are related to poor prognosis factors
in men with prostate cancer prior to treatment. BJU Int. 2012;
110(11 Pt B):E541-6.
15. Gurbuz C, Canat L, Atis G, Guner B, Caskurlu T. The role of
serum testosterone to prostate-specific antigen ratio as a
predictor of prostate cancer risk. Kaohsiung J Med Sci. 2012;
28: 649-53.